Loading...

We've got a brand new version of Simply Wall St! Try it out

General Cannabis

BST:7A7
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7A7
BST
$25M
Market Cap
  1. Home
  2. DE
  3. Commercial Services
Company description

General Cannabis Corp provides products and services to the regulated cannabis industry and non-cannabis customers in the United States. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • General Cannabis has significant price volatility in the past 3 months.
7A7 Share Price and Events
7 Day Returns
-14.6%
BST:7A7
0.6%
DE Commercial Services
1%
DE Market
1 Year Returns
-70.8%
BST:7A7
6.6%
DE Commercial Services
14.2%
DE Market
7A7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
General Cannabis (7A7) -14.6% 4.2% -33.1% -70.8% -75.6% -41.6%
DE Commercial Services 0.6% 1.3% 6.6% 6.6% -0.4% -5.8%
DE Market 1% 0% 6% 14.2% 8.7% 17.5%
1 Year Return vs Industry and Market
  • 7A7 underperformed the Commercial Services industry which returned 6.6% over the past year.
  • 7A7 underperformed the Market in Germany which returned 14.2% over the past year.
Price Volatility
7A7
Industry
5yr Volatility vs Market

Value

 Is General Cannabis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether General Cannabis is trading at an attractive price based on the cash flow it is expected to produce in the future. But as General Cannabis has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for General Cannabis. This is due to cash flow or dividend data being unavailable. The share price is €0.555.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for General Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are General Cannabis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:7A7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.41
OTCPK:CANN Share Price ** OTCPK (2019-12-12) in USD $0.64
Germany Commercial Services Industry PE Ratio Median Figure of 5 Publicly-Listed Commercial Services Companies 31.78x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 20.75x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of General Cannabis.

BST:7A7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:CANN Share Price ÷ EPS (both in USD)

= 0.64 ÷ -0.41

-1.53x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • General Cannabis is loss making, we can't compare its value to the DE Commercial Services industry average.
  • General Cannabis is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does General Cannabis's expected growth come at a high price?
Raw Data
BST:7A7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.53x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Commercial Services Industry PEG Ratio Median Figure of 52 Publicly-Listed Commercial Services Companies 1.41x
Germany Market PEG Ratio Median Figure of 262 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for General Cannabis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on General Cannabis's assets?
Raw Data
BST:7A7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.03
OTCPK:CANN Share Price * OTCPK (2019-12-12) in USD $0.64
Germany Commercial Services Industry PB Ratio Median Figure of 9 Publicly-Listed Commercial Services Companies 3.01x
Germany Market PB Ratio Median Figure of 578 Publicly-Listed Companies 1.89x
BST:7A7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:CANN Share Price ÷ Book Value per Share (both in USD)

= 0.64 ÷ -0.03

-22.98x

* Primary Listing of General Cannabis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • General Cannabis has negative assets, we can't compare the value of its assets to the DE Commercial Services industry average.

Next steps:

  1. Take a look at our analysis of 7A7’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through General Cannabis's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Commercial Services industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess General Cannabis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. General Cannabis has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is General Cannabis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as General Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
30.5%
Expected Commercial Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is General Cannabis expected to grow at an attractive rate?
  • Unable to compare General Cannabis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare General Cannabis's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare General Cannabis's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:7A7 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 30.5%
Germany Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 3.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:7A7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:7A7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 6 -6 -15
2019-06-30 5 -6 -17
2019-03-31 5 -6 -17
2018-12-31 5 -6 -17
2018-09-30 4 -5 -15
2018-06-30 4 -5 -12
2018-03-31 4 -4 -10
2017-12-31 4 -3 -8
2017-09-30 3 -3 1
2017-06-30 3 -3 -12
2017-03-31 3 -3 -12
2016-12-31 3 -2 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if General Cannabis is high growth as no earnings estimate data is available.
  • Unable to determine if General Cannabis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:7A7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from General Cannabis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:7A7 Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.41
2019-06-30 -0.48
2019-03-31 -0.47
2018-12-31 -0.49
2018-09-30 -0.46
2018-06-30 -0.43
2018-03-31 -0.42
2017-12-31 -0.40
2017-09-30 0.04
2017-06-30 -0.67
2017-03-31 -0.70
2016-12-31 -0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if General Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 7A7’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. General Cannabis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. General Cannabis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess General Cannabis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
General Cannabis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has General Cannabis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare General Cannabis's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • General Cannabis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare General Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare General Cannabis's 1-year growth to the Europe Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
General Cannabis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from General Cannabis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:7A7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 5.69 -15.48 12.41
2019-06-30 5.31 -17.44 12.37
2019-03-31 5.07 -17.02 12.40
2018-12-31 4.62 -16.97 12.14
2018-09-30 4.14 -14.60 10.63
2018-06-30 4.03 -12.13 9.60
2018-03-31 3.75 -10.06 8.28
2017-12-31 3.52 -8.22 7.44
2017-09-30 3.31 0.84 8.34
2017-06-30 3.14 -11.87 8.09
2017-03-31 3.01 -11.61 7.57
2016-12-31 2.98 -10.17 6.31
2016-09-30 2.89 -18.88 4.38
2016-06-30 2.67 -6.13 4.41
2016-03-31 2.40 -9.15 7.91
2015-12-31 1.76 -8.79 7.30
2015-09-30 1.13 -10.63 7.05
2015-06-30 0.60 -10.68 7.01
2015-03-31 0.25 -6.55 3.02
2014-12-31 0.24 -6.93 2.64
2014-09-30 0.18 -3.93 2.41
2013-12-31 -1.22 0.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if General Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if General Cannabis has efficiently used its assets last year compared to the DE Commercial Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if General Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess General Cannabis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
General Cannabis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is General Cannabis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up General Cannabis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • General Cannabis's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • General Cannabis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of General Cannabis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • General Cannabis has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from General Cannabis Company Filings, last reported 2 months ago.

BST:7A7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -1.09 2.25 0.63
2019-06-30 -0.10 1.11 0.79
2019-03-31 1.51 6.45 5.59
2018-12-31 4.55 5.27 7.96
2018-09-30 7.29 4.10 9.86
2018-06-30 9.93 2.64 10.17
2018-03-31 6.10 0.00 4.64
2017-12-31 3.51 2.55 5.04
2017-09-30 -6.09 2.65 0.25
2017-06-30 -7.81 2.37 0.28
2017-03-31 -12.14 2.21 0.41
2016-12-31 -0.19 2.62 0.77
2016-09-30 -13.95 1.88 1.06
2016-06-30 -0.38 2.59 0.05
2016-03-31 -0.86 2.28 0.01
2015-12-31 -0.21 1.94 0.06
2015-09-30 -0.92 2.04 0.10
2015-06-30 0.01 1.60 0.02
2015-03-31 0.20 1.24 0.10
2014-12-31 -3.52 1.06 0.17
2014-09-30 -0.17 0.77 1.12
2013-12-31 0.22 0.62 0.43
  • General Cannabis has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if General Cannabis's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • General Cannabis has less than a year of cash runway based on current free cash flow.
  • General Cannabis has less than a year of cash runway if free cash flow continues to grow at historical rates of 42.6% each year.
X
Financial health checks
We assess General Cannabis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. General Cannabis has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is General Cannabis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from General Cannabis dividends.
If you bought €2,000 of General Cannabis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate General Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate General Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:7A7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 3.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 2.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.3%
Germany Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as General Cannabis has not reported any payouts.
  • Unable to verify if General Cannabis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of General Cannabis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as General Cannabis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess General Cannabis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can General Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. General Cannabis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of General Cannabis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Feinsod
COMPENSATION $328,552
AGE 48
TENURE AS CEO 0.9 years
CEO Bio

Mr. Michael R. Feinsod has been Chief Executive Officer of General Cannabis Corp since August 5, 2019. Mr. Feinsod served as Interim Chief Executive Officer at General Cannabis Corp since January 07, 2019 until August 5, 2019. Mr. Feinsod serves as the President of ELK Associates Funding Corporation. Mr. Feinsod served as the Chief Executive Officer of Ameritrans Capital Corp. from October 10, 2008 to July 8, 2013 and served as its President from November 27, 2006 to July 8, 2013, Chief Compliance Officer from July 2008 to July 8, 2013 and also served as its Interim Treasurer since July 2010. Mr. Feinsod served as the Senior Vice President of Elk Associates unding Corporation, a subsidiary of Ameritrans Capital Corp. He served as a Managing Member of Infinity Capital, L.L.C. since January 1999. He served as Interim Chief Financial Officer of Ameritrans Capital Corp. from July 2010 to September 29, 2010. He served as an Investment Analyst and Portfolio Manager of Mark Boyar & Company, Inc. from June 1997 to January 1999. He served as a Secretary of Kingstone Companies, Inc. He has been Executive Chairman of the Board of General Cannabis Corp. since August 4, 2014 and served as its Interim Chief Executive Officer since January 2019. Mr. Feinsod served as the Chairman of Ameritrans Capital Corp. from November 11, 2010 to July 8, 2013. He served as a Director of Kingstone Companies, Inc. since October 23, 2008 until June 6, 2015. He served as a Director of Ameritrans Capital Corp. from December 22, 2005 to July 8, 2013 and Asta Funding Inc., since March 2001. He served as a Director of Elk Associates Funding Corporation, a subsidiary of Ameritrans Capital Corp. from December 2005 to July 8, 2013. He is admitted to practice law in New York and served as Associate in Corporate Law Department at Paul, Hastings, Janofsky & Walker LLP from 1996 to 1997. Mr. Feinsod holds a Juris Doctorate degree from Fordham University School of Law and a Bachelor of Arts from George Washington University.

CEO Compensation
  • Michael's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Michael's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the General Cannabis management team in years:

1.4
Average Tenure
  • The average tenure for the General Cannabis management team is less than 2 years, this suggests a new team.
Management Team

Michael Feinsod

TITLE
Executive Chairman of the Board & CEO
COMPENSATION
$329K
AGE
48
TENURE
0.9 yrs

Brian Andrews

TITLE
Chief Financial Officer
COMPENSATION
$296K
AGE
56
TENURE
2.3 yrs

Rich Cardinal

TITLE
Vice President of Operations
TENURE
0.5 yrs

Hunter Garth

TITLE
Vice President of Corporate Development
COMPENSATION
$319K

Bryan DeHaven

TITLE
Managing Director of Chiefton Supply Co
TENURE
2.3 yrs

Dave Hirst

TITLE
Managing Director of Chiefton Supply
TENURE
0.8 yrs

Jessica Bast

TITLE
VP & Controller
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the General Cannabis board of directors in years:

3.7
Average Tenure
48
Average Age
  • The tenure for the General Cannabis board of directors is about average.
Board of Directors

Michael Feinsod

TITLE
Executive Chairman of the Board & CEO
COMPENSATION
$329K
AGE
48
TENURE
5.3 yrs

Peter Boockvar

TITLE
Independent Director
COMPENSATION
$156K
AGE
50
TENURE
4.5 yrs

Mark Green

TITLE
Independent Director
COMPENSATION
$156K
AGE
44
TENURE
2.9 yrs

Seth Oster

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Jun 19 Buy Michael Feinsod Individual 11. Jun 19 11. Jun 19 1,100 €0.76 €835
X
Management checks
We assess General Cannabis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. General Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

General Cannabis Corp provides products and services to the regulated cannabis industry and non-cannabis customers in the United States. The company operates in four segments: Security and Cash Transportation Services (Security), Operations Consulting and Products (Operations), Consumer Goods and Marketing Consulting (Consumer Goods), and Capital Investments and Real Estate (Investments). The Security segment offers advanced security services, including on-site professional and cash transport to licensed cannabis cultivators and processing facilities, and retail shops; and security services to non-cannabis customers, such as hotels, apartment buildings, and retail. The Operations segment provides consulting services to the cannabis industry comprising obtaining licenses, compliance, cultivation, retail operations, logistical support, facility design and construction, and expansion of existing operations. The Consumer Goods segment provides design, branding, and marketing strategy consulting services to the cannabis industry, including sourcing and selling customer-specific apparel and accessories. It offers T-shirts, hats, hoodies, and accessories through an online shop, cannabis and non-cannabis retailers, and specialty T-shirt and gift shops. The Investments segment provides loans or revolving lines of credit; leases real estate properties; and invests in businesses. The company was formerly known as Advanced Cannabis Solutions, Inc. and changed its name to General Cannabis Corp in June 2015. General Cannabis Corp was incorporated in 2013 and is headquartered in Denver, Colorado.

Details
Name: General Cannabis Corp
7A7
Exchange: BST
Founded: 2013
$22,547,728
39,497,480
Website: http://www.generalcann.com
Address: General Cannabis Corp
6565 East Evans Avenue,
Denver,
Colorado, 80224,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CANN Common Stock Pink Sheets LLC US USD 15. Aug 2013
BST 7A7 Common Stock Boerse-Stuttgart DE EUR 15. Aug 2013
Number of employees
Current staff
Staff numbers
82
General Cannabis employees.
Industry
Security and Alarm Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/13 21:53
End of day share price update: 2019/12/12 00:00
Last earnings filing: 2019/11/08
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.